Shenzhen BioX Medical Co., Ltd. is a globally recognized manufacturer specializing in high-fidelity molecular diagnostic analysis systems, genetic testing solutions, and specialized clinical laboratory equipment. Established in 2017 and headquartered in Shenzhen—China’s premier hub for biotechnological innovation—the company bridges the gap between advanced R&D and large-scale manufacturing.
With a focus on transcriptomics and nucleic acid detection, BioX Medical serves a diverse clientele including hospitals, research institutions, public health organizations, and biotech firms. Our portfolio integrates automation with sophisticated data management, ensuring that every RNA Analysis Platform we manufacture meets the rigorous demands of modern precision medicine.
Navigating the shift from bulk analysis to single-cell precision and spatial transcriptomics.
Next-generation platforms are moving beyond raw data generation. BioX Medical is integrating AI algorithms to provide real-time RNA-seq analysis, reducing the "time-to-insight" for clinicians from days to hours.
Our roadmap includes the development of handheld nucleic acid testing devices that maintain the analytical sensitivity of laboratory-grade equipment, suitable for decentralized testing environments.
Eliminating human error through full automation of the extraction, amplification, and detection phases. Our platforms utilize advanced microfluidics to minimize reagent waste and maximize precision.
How RNA Analysis Platforms empower diverse sectors through high-throughput capabilities.
RNA analysis is critical for identifying gene fusions and expression patterns in tumors. Our platforms support Biomarker Discovery, enabling oncologists to prescribe targeted therapies based on the unique transcriptomic profile of the patient.
The global demand for rapid pathogen detection has redefined the market. Our Real-Time PCR and Nucleic Acid Testing Platforms are designed for high-sensitivity detection of viral and bacterial RNA, providing crucial data for pandemic preparedness and public health response.
Manufacturers are increasingly applying RNA analysis to crop science. By monitoring gene expression in response to environmental stressors, agricultural companies can develop more resilient crop varieties, ensuring food security in a changing climate.
Why BioX Medical is the preferred partner for global manufacturing.
From PCB design to plastic injection molding, BioX Medical controls the majority of the production cycle. This vertical integration reduces dependencies on external suppliers and mitigates the risk of supply chain disruptions.
Our 9,000 sqm facility utilizes IoT-enabled production lines. Real-time monitoring of machine performance ensures consistent quality control and allows for rapid scaling of production to meet urgent global demands.
Leveraging Shenzhen's unique electronic ecosystem, we provide high-end RNA Analysis Platforms at a competitive price point without compromising on E-E-A-T standards or international certifications.
Ensuring your diagnostic solutions meet international regulatory standards.
For global enterprises, compliance is non-negotiable. Shenzhen BioX Medical Co., Ltd. maintains strict adherence to quality management systems, including:
Beyond certifications, we offer Localization Services, including UI translation, custom reporting formats, and regional cloud server integration to comply with local data privacy laws (such as GDPR or HIPAA).
Tailored OEM/ODM services for distributors and diagnostic giants.
Global procurement officers are increasingly looking for "Information Gain"—suppliers who don't just provide a box, but a comprehensive solution. BioX Medical provides:
Fully branded hardware and software interfaces tailored to your corporate identity.
Established routes to Europe, North America, and Asia-Pacific with robust export handling.
Dedicated engineering support for your local service teams to ensure seamless deployment.
Expert insights into RNA analysis platform selection and manufacturing.
A: RNA analysis requires specific handling to preserve transcript stability and often includes reverse transcription steps. Our platforms are optimized for the high dynamic range and sensitivity needed to detect low-abundance RNA transcripts compared to genomic DNA.
A: Yes. Through our ODM services, we can configure our hardware and software to optimize detection for proprietary biomarker signatures, providing a "turn-key" solution for diagnostic developers.
A: We provide a tiered support system including remote diagnostic capabilities built into the platforms, comprehensive video training libraries, and local distributor partnerships for on-site maintenance.
A: Depending on the level of customization, standard manufacturing lead times range from 4 to 8 weeks. Our Factory 4.0 infrastructure allows for rapid scaling for urgent pandemic-related requirements.
Quality Control and Innovation at the Heart of Shenzhen.
BioX Medical
